Funding
Series A · Biotech

IMU Biosciences raises $53m Series A for immune profiling

IQ Capital, Molten Ventures, British Business Bank and Meltwind participated in the financing.

Updated Oct 16, 2026By RoundOS Funding desk

IMU Biosciences raised $53 million in Series A financing on June 2. Participants included IQ Capital, Molten Ventures, British Business Bank and Meltwind. The company profiles human immune systems using multi-omic analysis and machine learning.

Funding history

Series A · This round$53M

Sources

  1. IMU Biosciencesprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related